Last $10.56 USD
Change Today +0.48 / 4.76%
Volume 422.1K
VNDA On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

H. Thomas Watkins

Chairman, Chairman of Nominating/Corporate Governance Committee and Member of Compensation Committee, Vanda Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 121 board members in 4 different organizations across 4 different industries.

See Board Relationships
61$113,451

Background*

Mr. H. Thomas Watkins, also known as Tom, served as the Chief Executive Officer and President of Human Genome Sciences Inc., from November 22, 2004 to August 2012. Mr. Watkins has over 20 years of experience at Abbott Laboratories and its affiliates in the U.S. and Asia. He served as the President of TAP Pharmaceutical Products Inc. from September 1998 to August 2004, which is jointly owned by Abbott Laboratories and Takeda Pharmaceutical Company Limited. He joined Abbott ...

Read Full Background

Corporate Headquarters*

2200 Pennsylvania Avenue NW
Washington, District Of Columbia 20037

United States

Phone: 202-734-3400
Fax: 202-296-1450

Board Members Memberships*

Chairman
2004-2012
Former Chief Executive Officer, President and Director
2006-Present
Chairman, Chairman of Nominating/Corporate Governance Committee and Member of Compensation Committee
2014-Present
Director, Chairman of Nominating & Corporate Governance Committee and Member of Transaction Committee

Education*

Bachelor's Degree
College of William & Mary
MBA
The University of Chicago Booth School of Business

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

Exercisable Options132,499
Unexercisable Options7,501
Total Number of Options140,000

Total Compensation*

Total Annual Cash Compensation$41,301
Total Calculated Compensation$113,451
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNDA:US $10.56 USD +0.48

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Lechleiter Ph.D.Chairman, Chief Executive Officer and President
Eli Lilly and Company
$1.5M
Pascal Soriot Chief Executive Officer, Executive Director and Member of Disclosure Committee
AstraZeneca PLC
3.0M GBP
Christopher A. Viehbacher Chief Executive Officer, Director and Member of Strategy Committee
Sanofi
€3.0M
Masayo Tada Chief Executive Officer, President, Representative Director and Chairman of Risk Management Committee
Sumitomo Dainippon Pharma Co., Ltd.
--
Glenn A. Oclassen Sr.Chairman of the Board, Chief Executive Officer and President
Transcept Pharmaceuticals, Inc.
$560.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.